Search
Displaying 381–390 of 737 for “retinitis clinical trial”
-
Consortium Genetically Tests 40 Percent of People in Israel with IRDs
Research NewsPatient benefits from genetic testing for IRDs include confirmation of their clinical diagnosis, identification of the disease inheritance pattern and risk for other family members, and determination of human studies for emerging therapies that may be appropriate for them.
-
Disease
Often diagnosed in childhood or adolescence, Stargardt disease is an inherited form of macular degeneration causing central vision loss. The condition is sometimes referred to as juvenile or early onset macular degeneration.
-
Leber Congenital Amaurosis (LCA)
DiseaseLCA is a group of inherited retinal diseases causing blindness or severe vision loss in early childhood.
-
Stem-Cell Therapy Clinics Remain Inadequately Regulated, Pose Risk to Patients
Research NewsIf a clinic is charging for a stem-cell treatment or procedure for an IRD, it is probably not legit. The expense to the patient is a major red flag.
-
Research News
Dr. Weleber became the 10th recipient of the Foundation’s highest honor, named after FFB co-founder Lulie Gund, during the opening lunch of the VISIONS 2016 conference.
-
Gene Therapy Strengthens the Retina's Connection to the Brain
Research NewsWhat happens to the brain when the eye is enabled to see through gene therapy? Would the brain and eye restart their partnership? We now know the answer is yes.
-
An FFB Board Member’s Perspective on Her Experience with Acupuncture
Beacon StoriesMoira Shea describes her experience with acupuncture.
-
How an FDA-Approved Retinal Prosthesis Came To Be
Research NewsThe Argus II Retinal Prosthesis System was recently granted market approval by the U.S. Food and Drug Administration (FDA), which marks a significant milestone in the development of a therapy that has spanned more than 20 years.
-
Safely Harnessing the Power of Stem Cells
Research NewsIn the not-too-distant future, researchers will be able to turn stem cells into new photoreceptors for people who have lost vision to a retinal disease. But they must also carefully harness their power to ensure positive consequences.
